---
title: "MSD wins FDA approval for cholesterol pill to help plug Keytruda void"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293018081.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-17T09:31:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293018081.md)
  - [en](https://longbridge.com/en/news/293018081.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293018081.md)
---

# MSD wins FDA approval for cholesterol pill to help plug Keytruda void

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Is Merck (MRK) Undervalued As KEYTRUDA Wins New FDA Approvals And Phase 3 Success?](https://longbridge.com/en/news/292854144.md)
- [Aspen Pharmacare signs voluntary licensing deal with MSD for once-monthly HIV prevention pill MK-8527](https://longbridge.com/en/news/293755123.md)
- [Adult epilepsy market to reach $17.bn across 7MM by 2035](https://longbridge.com/en/news/293805836.md)
- [Sanofi abandons eczema drug approval efforts in another blow to OX40 class](https://longbridge.com/en/news/293763629.md)
- [What Ojemda’s JCA reveals about new era of clinical HTA in Europe](https://longbridge.com/en/news/293247752.md)